Market Place
Sourcing Support
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08 May 2023 //
GLOBENEWSWIRE
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Apr 2023 //
GLOBENEWSWIRE
TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results
23 Mar 2023 //
GLOBENEWSWIRE
Adaptimmune & TCR² Announce Combination to Create Cell Therapy Company
06 Mar 2023 //
GLOBENEWSWIRE
TCR2 Therapeutics to Present at SVB Securities Global Biopharma Conference 2023
08 Feb 2023 //
GLOBENEWSWIRE
TCR² first began layoffs back in August
13 Jan 2023 //
FIERCE BIOTECH
TCR² Therapeutics Announces Pipeline Priorities for 2023
05 Jan 2023 //
GLOBENEWSWIRE
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule
05 Jan 2023 //
GLOBENEWSWIRE
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule
01 Dec 2022 //
GLOBENEWSWIRE
TCR² Therapeutics to Present at the Piper Sandler Healthcare Conference
23 Nov 2022 //
GLOBENEWSWIRE
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Oct 2022 //
GLOBENEWSWIRE
TCR2`s cell therapy racks up 22% response rate in solid tumors
28 Sep 2022 //
FIERCEBIOTECH
TCR² Therapeutics to Announce Complete Phase 1 Portion of the Gavo-cel Ph 1/2
27 Sep 2022 //
GLOBENEWSWIRE
TCR² Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit
26 Sep 2022 //
GLOBENEWSWIRE
TCR² Therapeutics Reports Second Quarter 2022 Financial Results
08 Aug 2022 //
GLOBENEWSWIRE
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Aug 2022 //
GLOBENEWSWIRE
TCR2 Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Jul 2022 //
GLOBENEWSWIRE
TCR2 Therapeutics Appoints Industry and Finance Veteran Eric Sullivan as CFO
27 Jun 2022 //
GLOBENEWSWIRE
TCR2 Therapeutics to Participate in Two Upcoming Conferences in June
01 Jun 2022 //
GLOBENEWSWIRE
TCR2 Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Jun 2022 //
GLOBENEWSWIRE
TCR2 Therapeutics Reports First Quarter 2022 Financial Results
12 May 2022 //
GLOBENEWSWIRE
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 May 2022 //
GLOBENEWSWIRE
TCR2 Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Apr 2022 //
GLOBENEWSWIRE
TCR² Therapeutics Reports Q4 2021 Financial Results
22 Mar 2022 //
GLOBENEWSWIRE
TCR² Tx to Highlight Off-the-Shelf TRuC-T Cell at AACR
08 Mar 2022 //
GLOBENEWSWIRE
TCR2 Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Mar 2022 //
GLOBENEWSWIRE
TCR² Therapeutics Announces 2022 Strategic Priorities and Anticipated Milestones
10 Jan 2022 //
GLOBENEWSWIRE
TCR² Therapeutics to Present at the J.P. Morgan Healthcare Conference
07 Jan 2022 //
GLOBENEWSWIRE
TCR², Arbor Bio Collaborate to Advance Allogeneic TRuC-T Cell Therapies
04 Jan 2022 //
GLOBENEWSWIRE
TCR² Therapeutics Announces Expansion of U.S. Manufacturing Capacity
01 Nov 2021 //
BAKERSFIELD
TCR² TherapAnnounces Clinical Trial Collaboration Agreement with Bristol Myers
25 Oct 2021 //
GLOBENEWSWIRE
TCR² Therapeutics Reviews Pipeline and Strategy at R&D Day
20 Oct 2021 //
GLOBENEWSWIRE
Innovent & GenFleet deal for KRAS inhibitor; TCR2 receives FDA`s ODD on gavo-cel
02 Sep 2021 //
ENDPTS
TCR² Therapeutics Announces Priti Hegde Joins Its Board of Directors
26 Aug 2021 //
GLOBENEWSWIRE
TCR2 Therapeutics Appoints Chief Technical Officer
21 Jul 2021 //
CONTRACT PHARMA
TCR² Presentations at American Association of Cancer Research (AACR)
10 Mar 2021 //
GLOBENEWSWIRE
TCR² Therapeutics, ElevateBio Expand TC-210 Mfg. Capacity
11 Nov 2020 //
CONTRACT PHARMA
TCR2`s T-cell therapy curbs solid tumors in early phase 1 data
27 Jul 2020 //
FIERCE BIOTECH
TCR² Therapeutics to Announce Interim Data from Ph1/2 Clinical Trial of TC-210
24 Jul 2020 //
GLOBENEWSWIRE
TCR² Therapeutics Announces Veteran Finance Executive Stephen Webster
04 May 2020 //
GLOBENEWSWIRE
